Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
BURNABY, British Columbia, May 01, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, May 8, 2018. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4982979. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as epilepsy, migraine and pain. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Vice President, Corporate Affairs & Investor Relations
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]
